These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 1409866)
41. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. Aravagiri M; Marder SR; Van Putten T; Marshall BD J Chromatogr B Biomed Appl; 1994 Jun; 656(2):373-81. PubMed ID: 7987490 [TBL] [Abstract][Full Text] [Related]
50. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Jann MW; Chang WH; Lam YW; Hwu HG; Lin HN; Chen H; Chen TY; Lin SK; Chien CP; Davis CM Prog Neuropsychopharmacol Biol Psychiatry; 1992 Mar; 16(2):193-202. PubMed ID: 1579637 [TBL] [Abstract][Full Text] [Related]
51. Plasma noradrenaline and clinical psychopathology in schizophrenia. A correlation analysis. Dajas F; Barbeito L; Martinez-Pesquera G; Lista A; Puppo D; Puppo-Touriz H Neuropsychobiology; 1983; 10(2-3):70-4. PubMed ID: 6674828 [TBL] [Abstract][Full Text] [Related]
52. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism. Iwahashi K; Anemo K; Nakamura K; Fukunishi I; Igarashi K Neuropsychobiology; 2001; 44(3):126-8. PubMed ID: 11586051 [TBL] [Abstract][Full Text] [Related]
53. Interindividual variabilities in haloperidol interconversion and the reduced haloperidol/haloperidol ratio. Lam YW; Chang WH; Jann MW; Chen H Neuropsychopharmacology; 1992 Aug; 7(1):33-9. PubMed ID: 1524655 [TBL] [Abstract][Full Text] [Related]
54. Serum level of haloperidol and its clinical significance. Itoh H; Yagi G; Ohtsuka N; Iwamura K; Ichikawa K Prog Neuropsychopharmacol; 1980; 4(2):171-83. PubMed ID: 7403350 [No Abstract] [Full Text] [Related]
55. Total and free serum haloperidol levels in schizophrenic patients and the effect of age thioridazine and fatty acid on haloperidol-serum protein binding in vitro. Rowell FJ; Hui SM; Fairbairn AF; Eccleston D Br J Clin Pharmacol; 1981 Apr; 11(4):377-82. PubMed ID: 7259931 [TBL] [Abstract][Full Text] [Related]
56. High-performance liquid chromatography of haloperidol in serum at the concentrations achieved during chronic therapy. McBurney A; George S J Chromatogr; 1984 Jun; 308():387-92. PubMed ID: 6746832 [No Abstract] [Full Text] [Related]
57. Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Lane HY; Lin HN; Hu OY; Chen CC; Jann MW; Chang WH Prog Neuropsychopharmacol Biol Psychiatry; 1997 Feb; 21(2):299-311. PubMed ID: 9061775 [TBL] [Abstract][Full Text] [Related]
58. [The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients]. Someya T; Shibasaki M; Takahashi S Yakubutsu Seishin Kodo; 1989 Jun; 9(2):207-15. PubMed ID: 2816093 [TBL] [Abstract][Full Text] [Related]
59. Radioimmunoassay of haloperidol in human serum: correlation of serum haloperidol with serum prolactin. Poland RE; Rubin RT Life Sci; 1981 Nov; 29(18):1837-45. PubMed ID: 7311717 [No Abstract] [Full Text] [Related]
60. Measurement of haloperidol and reduced haloperidol in human plasma using reversed-phase high-performance liquid chromatography. Miller RL; DeVane CL J Chromatogr; 1986 Jan; 374(2):405-8. PubMed ID: 3958099 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]